Targeted & controlled bone healing
14 Sep 18
Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

MEDIA RELEASE

Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

Schlieren (Zurich), Switzerland, September 14, 2018 – Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, announced today that it will host a Key Opinion Leader (KOL) luncheon on establishing the new gold standard in bone regeneration on Thursday, September 20 at the Hotel Richemond in Geneva, Switzerland.

 

The KOL event will feature presentations by KOLs John Sutcliffe MBChB FRCS(Ed) FRCS(SN), from the London Spine Clinic, and Andrew A. Sama, MD, from the Hospital for Special Surgery, Weill Cornell Medical College, who will discuss the scientific rationale of Kuros’s lead programs, Fibrin/PTH and MagnetOS, as well the overall treatment landscape in both Europe and the United States, and the commercial potential of Kuros’s innovative portfolio in bone regeneration.

 

Kuros’s CEO Joost de Bruijn will give a short investor presentation highlighting the Company’s progress to date and upcoming milestones.

 

John Sutcliffe is Triage Consultant Spinal Neurosurgeon & Lead Clinician, London Spine Clinic, having trained in Edinburgh and qualifying in 1983. He was appointed as a consultant neurosurgeon in 1993 and has since concentrated exclusively in the management of patients with spinal disorders. He pioneered the concept of the multi-disciplinary team approach to spinal disorders, setting up the London Spine Clinic in 1997, the first hospital of its kind in the UK at the time. He resigned from the NHS in 2000 but remains an Emeritus Consultant at Barts' and the London NHS Trust. As training director in the NHS and at the London Spine Clinic and London Clinic Hospital, Mr. Sutcliffe has trained many young spinal surgeons in his 25 years as a consultant.

 

Dr. Andrew Sama serves as Director of Spine Surgery Fellowship at Hospital for Special Surgery & Associate Professor of Clinical Orthopaedic Surgery, Orthopaedic Surgery, Weill Cornell Medical College. Dr. Andrew Sama specializes in the management of all traumatic, degenerative, and deformity-related conditions of the cervical, thoracic, and lumbosacral spine. He has received a number of research grants, including funding from the National Institutes of Health. Dr. Sama is involved in product development and has helped design several orthopedic implant devices. He has published articles in numerous peer-reviewed medical journals and co-edited a textbook titled "Lateral Access Minimally Invasive Spine Surgery." He is on the editorial board of Current Reviews in Musculoskeletal Medicine and serves as a reviewer for the journals Spine and Clinical Orthopaedics and Related Research.

 

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.  A live webcast and replay will be accessible via the link here.  If you would like to ask a question during the live Q&A, please submit your request via email.



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
14 Sep 18
Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

MEDIA RELEASE

Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

Schlieren (Zurich), Switzerland, September 14, 2018 – Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, announced today that it will host a Key Opinion Leader (KOL) luncheon on establishing the new gold standard in bone regeneration on Thursday, September 20 at the Hotel Richemond in Geneva, Switzerland.

 

The KOL event will feature presentations by KOLs John Sutcliffe MBChB FRCS(Ed) FRCS(SN), from the London Spine Clinic, and Andrew A. Sama, MD, from the Hospital for Special Surgery, Weill Cornell Medical College, who will discuss the scientific rationale of Kuros’s lead programs, Fibrin/PTH and MagnetOS, as well the overall treatment landscape in both Europe and the United States, and the commercial potential of Kuros’s innovative portfolio in bone regeneration.

 

Kuros’s CEO Joost de Bruijn will give a short investor presentation highlighting the Company’s progress to date and upcoming milestones.

 

John Sutcliffe is Triage Consultant Spinal Neurosurgeon & Lead Clinician, London Spine Clinic, having trained in Edinburgh and qualifying in 1983. He was appointed as a consultant neurosurgeon in 1993 and has since concentrated exclusively in the management of patients with spinal disorders. He pioneered the concept of the multi-disciplinary team approach to spinal disorders, setting up the London Spine Clinic in 1997, the first hospital of its kind in the UK at the time. He resigned from the NHS in 2000 but remains an Emeritus Consultant at Barts' and the London NHS Trust. As training director in the NHS and at the London Spine Clinic and London Clinic Hospital, Mr. Sutcliffe has trained many young spinal surgeons in his 25 years as a consultant.

 

Dr. Andrew Sama serves as Director of Spine Surgery Fellowship at Hospital for Special Surgery & Associate Professor of Clinical Orthopaedic Surgery, Orthopaedic Surgery, Weill Cornell Medical College. Dr. Andrew Sama specializes in the management of all traumatic, degenerative, and deformity-related conditions of the cervical, thoracic, and lumbosacral spine. He has received a number of research grants, including funding from the National Institutes of Health. Dr. Sama is involved in product development and has helped design several orthopedic implant devices. He has published articles in numerous peer-reviewed medical journals and co-edited a textbook titled "Lateral Access Minimally Invasive Spine Surgery." He is on the editorial board of Current Reviews in Musculoskeletal Medicine and serves as a reviewer for the journals Spine and Clinical Orthopaedics and Related Research.

 

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.  A live webcast and replay will be accessible via the link here.  If you would like to ask a question during the live Q&A, please submit your request via email.